Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

ZoBio And Domainex Join To Serve Forma

by Rick Mullin
December 15, 2014 | A version of this story appeared in Volume 92, Issue 50

[+]Enlarge
Credit: Domainex
A Domainex scientist generates protein variants for biological targets.
A Domainex scientist generating protein variants for challenging biological targets.
Credit: Domainex
A Domainex scientist generates protein variants for biological targets.

ZoBio and Domainex have formed a partnership to provide NMR-based structural biology services for drug targets discovered by Forma Therapeutics, a Massachusetts drug company. Netherlands-based ZoBio will design and express protein variants suitable for structural studies to complement X-ray crystallography used by Forma in oncology research. Domainex, based in Cambridge, England, will apply its Combinatorial Domain Hunting technology to generate protein variants for targets not previously amenable to structural studies.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.